Paolo Bonanni1, Pascaline Faivre2, Pier Luigi Lopalco3, Elmar A Joura4, Tobias Bergroth5, Stefan Varga6, Nathalie Gemayel7, Rosybel Drury8. 1. Department of Health Sciences, University of Florence , Florence, Italy. 2. Market Access Vaccines, MSD , Lyon, France. 3. Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa , Pisa, Italy. 4. Department of Gynecology and Obstetrics, Comprehensive Cancer Center, Medical University of Vienna , Vienna, Austria. 5. Center for Observational and Real-world Evidence, MSD , Stockholm, Sweden. 6. Center for Observational and Real-world Evidence, Merck & Co, Inc , Kenilworth, NJ, USA. 7. Health Economics & Market Access, Amaris Consulting , Barcelona, Spain. 8. Global Vaccines Medical & Scientific Affairs, MSD , Lyon, France.
Abstract
Background: There is a need to better understand HPV vaccination (HPVv) implementation in WHO Europe Region (WHO/ER), including recommendations, funding, and vaccination coverage rates (VCR). Methods: A targeted literature review (up to 31 January 2020) was conducted using national health ministry websites, WHO database, and published studies from WHO/ER countries (n = 53). HPVv recommendations and funding data (target age, gender, schedule, setting, target and monitored VCR) for primary and catch-up cohorts were collected. Results: National recommendations for HPVv exist in 46/53 (87%) countries, of which 38 (83%), 2 (4%), and 6 (13%) countries provided full, partial, or no funding, respectively, for the primary cohort. Fully or partially funded HPVv was provided for girls only in 25/53 (47%) countries and for both boys and girls in 15/53 (28%) countries. HPVv catch-up was fully or partially funded in 14/53 (26%) countries. Among 40 countries with a national immunization program (NIP), monitored VCRs ranged from 4.3% to 99% (n = 30). Of the 10 countries reporting VCR targets, only Portugal exceeded its target. Conclusion: Of the 53 WHO/ER countries, 40 have funded HPVv NIPs, among which 30 report VCRs. Additional efforts are required to ensure HPVv NIPs are fully funded and high VCRs maintained.
Background: There is a need to better understand HPV vaccination (HPVv) implementation in WHO Europe Region (WHO/ER), including recommendations, funding, and vaccination coverage rates (VCR). Methods: A targeted literature review (up to 31 January 2020) was conducted using national health ministry websites, WHO database, and published studies from WHO/ER countries (n = 53). HPVv recommendations and funding data (target age, gender, schedule, setting, target and monitored VCR) for primary and catch-up cohorts were collected. Results: National recommendations for HPVv exist in 46/53 (87%) countries, of which 38 (83%), 2 (4%), and 6 (13%) countries provided full, partial, or no funding, respectively, for the primary cohort. Fully or partially funded HPVv was provided for girls only in 25/53 (47%) countries and for both boys and girls in 15/53 (28%) countries. HPVv catch-up was fully or partially funded in 14/53 (26%) countries. Among 40 countries with a national immunization program (NIP), monitored VCRs ranged from 4.3% to 99% (n = 30). Of the 10 countries reporting VCR targets, only Portugal exceeded its target. Conclusion: Of the 53 WHO/ER countries, 40 have funded HPVv NIPs, among which 30 report VCRs. Additional efforts are required to ensure HPVv NIPs are fully funded and high VCRs maintained.
Authors: Ivette Maldonado; Manuel Plata; Mauricio Gonzalez; Alfonso Correa; Claudia Nossa; Anna R Giuliano; Elmar A Joura; Alex Ferenczy; Brigitte M Ronnett; Mark H Stoler; Hao Jin Zhou; Amita Joshi; Rituparna Das; Oliver Bautista; Thomas Group; Alain Luxembourg; Alfred Saah; Ulrike Kirsten Buchwald Journal: Hum Vaccin Immunother Date: 2022-07-19 Impact factor: 4.526
Authors: Philippe Gorphe; Pierre Blanchard; Gabriel C T E Garcia; Marion Classe; Caroline Even; Stéphane Temam; Ingrid Breuskin Journal: BMC Cancer Date: 2022-09-20 Impact factor: 4.638
Authors: Nadja Taumberger; Elmar A Joura; Marc Arbyn; Maria Kyrgiou; Jalid Sehouli; Murat Gultekin Journal: Int J Gynecol Cancer Date: 2022-07-12 Impact factor: 4.661
Authors: Rosa De Vincenzo; Nicola Caporale; Valentina Bertoldo; Caterina Ricci; Maria Teresa Evangelista; Nicolò Bizzarri; Luigi Pedone Anchora; Giovanni Scambia; Giovanni Capelli Journal: Vaccines (Basel) Date: 2021-06-12
Authors: Noelia López; Ignacio Salamanca de la Cueva; Edelmiro Vergés; Eva Suárez Vicent; Almudena Sánchez; Ana Belén López; María Belén Panizo-Santos; María Garcés-Sánchez; Abián Montesdeoca; Antonio José Rivera; Manuel Suárez Cotarelo Journal: Hum Vaccin Immunother Date: 2022-02-01 Impact factor: 3.452